| Old Articles: <Older 8681-8690 Newer> |
|---|
 |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.   |
Pharmaceutical Executive
September 1, 2013 |
Country Report: Indonesia Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia's healthcare system has turned "improving quality" into the top priority of the government of Indonesia. |
Pharmaceutical Executive
September 1, 2013
Stan Bernard |
The Drug Combination Competition Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share. |
Pharmaceutical Executive
September 1, 2013
Jill Wechsler |
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. |
Pharmaceutical Executive
September 1, 2013
Ben Comer |
Share of Screen: Prioritizing Electronic Health Records Are electronic health records a viable channel for engagement? |
Pharmaceutical Executive
September 1, 2013 |
T-TIPing the Balance in Industry's Favor By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going. |
Pharmaceutical Executive
September 1, 2013
Jordan Sarver |
Pathology in the Era of Personalized Medicine With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided. |
Pharmaceutical Executive
September 1, 2013
Al Topin |
The Art and Science of Creating Discomfort What does a challenger pharmaceutical brand need to do? |
Pharmaceutical Executive
September 1, 2013
William Looney |
Trying to Control Pharma Costs? A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life altering diseases. |
Chemistry World
September 11, 2013
Phillip Broadwith |
First biosimilar antibody drugs approved in Europe The European commission has given final marketing approval to the first generic versions of monoclonal antibody drug infliximab (Johnson & Johnson's Remicade). |
| <Older 8681-8690 Newer> Return to current articles. |
